Search

News How Does the Long-Term Effect of Beta Blocker Use Affect Clinical Outcomes in Patients After Myocardial Infarction?

In patients after myocardial infarction (MI), beta blockers (BB) still hold an important place in secondary prevention according to recommended procedures. However, the question could be their long-term effect on clinical outcomes, as different results can be found in the literature –⁠ this fact led the authors of the work cited below to perform a systematic review and meta-analysis of studies dedicated to this issue.

Source: Cardiovascular Continuum 25. 10. 2023

News Progress on Lorlatinib –⁠ What's Next?

Lorlatinib is currently mainly used in the 2nd and later lines of treatment for non-small cell lung cancer (NSCLC) with ALK gene rearrangement. Clinical research is now focusing on the question of how to proceed with patients who experience disease progression during lorlatinib treatment in later lines of therapy. It seems that one of the options might actually be to do nothing –⁠ to continue with lorlatinib.

Source: Genetic Profile and Treatment of NSCLC 17. 5. 2022

News Reversal of Dabigatran Effects with Idarucizumab in Patients Requiring Urgent Procedures: Subanalysis of the RE-VERSE AD Study

The effect of idarucizumab as a reversal agent in patients treated with dabigatran in situations requiring urgent surgery or other invasive procedures was evaluated in a subanalysis from the RE-VERSE AD study published in 2021.

Source: Anticoagulant Treatment 18. 11. 2021

News Therapy with Cyclosporine in the Context of the Coronavirus Pandemic

The rapid spread of the SARS-CoV-2 virus and the associated COVID-19 disease pandemic raises concerns about possible risks associated with immunosuppressive treatment of autoimmune diseases. Specifically, does the use of cyclosporine increase the risk of infection, or does it act protectively?

Source: Systemic treatment of atopic dermatitis, asthma, and chronic rhinosinusitis with nasal polyposis – Type 2 inflammation 14. 4. 2021

Články časopisu Gynecologic robotic surgery and our initial experience

Author of the article: R. Pilka, P. Dzvinčuk Source: Česká gynekologie | 6/2010 20. 12. 2010

News Idarucizumab reverses the anticoagulant effect of dabigatran even in patients with impaired renal function –⁠ clinical practice commentary

Along with the results of a subanalysis of the RE-VERSE AD study, which demonstrated the efficacy of idarucizumab in reversing the anticoagulant effect of dabigatran regardless of the level of renal function impairment, the October issue of the Journal of the American College of Cardiology also featured an editorial commentary by Californian cardiologists on its conclusions.

Source: Anticoagulant Treatment 10. 2. 2020

News Atectura® and Enerzair® from May 1, 2021 with Health Insurance Coverage

The fixed combination of indacaterol acetate (LABA) and mometasone furoate (ICS) Atectura® and the fixed triple combination, which in addition to these two substances also includes glycopyrronium bromide (LAMA), Enerzair® for maintenance inhalation treatment of bronchial asthma, approved in the EU last year, have established health insurance coverage in the Czech Republic from May 1, 2021. We bring a summary of the conditions for reimbursement.

Source: Asthma under control 2. 9. 2021

News Dravet Syndrome –⁠ Get to Know It

Dravet syndrome is a severe myoclonic epilepsy occurring in early childhood. It is classified as a rare progressive epileptic encephalopathy, characterized by generalized or lateralized clonic seizures often prolonged and linked to febrile infections. Other forms of seizures later appear, leading to deterioration in psychomotor development and the onset of mental retardation. Early diagnosis and treatment are desirable.

Source: Rare Diseases in Neurology 2. 5. 2023

News Dyslipidemia in the General Practitioner's Office –⁠ Featuring LDL Cholesterol

Monitoring LDL cholesterol (LDL-c) levels is crucial in diagnosing hypercholesterolemia as it is directly linked to increased cardiovascular risk. What other tests should be performed upon detecting hypercholesterolemia and which medications can effectively help reduce LDL-c levels?

Source: Hypercholesterolemia 9. 12. 2021

News Comparison of Safety and Efficacy of Oral and Intravenous Administration of Combination NEPA in the Prophylaxis of Chemotherapy-Induced Nausea and Vomiting

Both oral and intravenous administration of a combination of netupitant (a neurokinin 1 receptor antagonist −⁠ NK1RA) with palonosetron (a 5-HT3 receptor antagonist) offer prevention of chemotherapy-induced nausea and vomiting (CINV) for up to 5 days after its administration. Although the i.v. form of netupitant (fosnetupitant) + palonosetron (NEPA) did not lead to injection site reactions or anaphylactic reactions in a Phase III study, hypersensitivity and anaphylactic reactions have been described with other i.v. administered NK1RAs. Thus, the aim of the study recently published in the journal The Oncologist was to evaluate the safety and efficacy of i.v. NEPA in women with breast cancer treated with anthracycline and cyclophosphamide-containing chemotherapy.

Source: Antiemetic Therapy 20. 1. 2020

News Quick Relief from Severe AD Symptoms –⁠ Dupilumab for Children Aged 6 Years and Older

Children aged 6-12 with severe atopic dermatitis (AD) have very limited treatment options. The studies presented below demonstrate how effective and safe dupilumab, a monoclonal antibody targeting interleukins 4 and 13, is in their case. Since October, this medication is newly covered even for children from 6 years of age.

Source: Systemic treatment of atopic dermatitis, asthma, and chronic rhinosinusitis with nasal polyposis – Type 2 inflammation 1. 11. 2021

News Increase in Hematocrit During Empagliflozin Treatment in a Diabetic Patient with Severe Anemia −⁠ A Case Study

In a case study involving a 78-year-old diabetic patient, where only the administration of empagliflozin led to the correction of severe anemia of unknown origin, Polish authors demonstrate the previously described pleiotropic effects of sodium-glucose cotransporter 2 inhibitors (SGLT2i, i.e., gliflozins) on increasing hematocrit levels.

Source: Heart Failure 26. 7. 2022

Články časopisu The heart transplantation

Author of the article: Lenka Špinarová, Jindřich Špinar, Jiří Vítovec Source: Vnitřní lékařství | 9/2018 15. 10. 2018

News Is exposure to mite allergens in breast milk or house dust a risk factor for asthma and allergies in childhood?

Exposure to mite allergens occurs early in life from both breast milk and house dust (especially bedding). The study presented below examined the impact of exposure to the dominant mite allergen Der p 1 on serum immunoglobulin E (IgE) levels and the development of bronchial asthma in childhood.

Source: Dust Mite Allergy 23. 2. 2023

News Generic Substitution of Levothyroxine in Practice

The active ingredient levothyroxine is found in a significant number of medicinal products (MP) in the Czech Republic. The question of its generic substitution remains current, primarily because the previously published data tend to call for caution due to possible adverse effects on the patient.

Source: Thyroid Disorders 22. 2. 2024